COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00765466
Recruitment Status : Terminated (Study transferred out of McGill because PI relocted to another insitution.)
First Posted : October 3, 2008
Last Update Posted : March 14, 2019
Information provided by:
McGill University

Brief Summary:
This is an open label, Phase II, multi-center study designed to evaluate the effect of AVR118 when administered to patients with systemic symptoms related to recurrent or metastatic cancers who may or may not be undergoing anti-cancer treatment. During the initial, induction treatment phase of the study, AVR118, 4.0 mL, will be given subcutaneously each day for 28 days. Patients who respond to the trial period dosing will be eligible to continue on AVR118 if they and their physicians believe it would be beneficial, and if no safety concerns are raised.

Condition or disease Intervention/treatment Phase
Cancer Drug: AVR118 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies
Study Start Date : October 2007
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Intervention Details:
  • Drug: AVR118
    daily doses of 4.0 mL AVR118 subcutaneously

Primary Outcome Measures :
  1. Karnofsky Performance Status Disease-related symptoms: ESAS and PG-SGA Anorexia Weight Lean Body Mass, Triceps skin fold, and grip strength

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumor cancer, leukemia, lymphoma, or multiple myeloma.
  • Concurrent anti-cancer treatment, such as chemotherapy or radiation therapy is permitted except for neo-adjuvant or adjuvant programs.
  • Between the ages of 18-85.
  • Symptoms of recurrent or metastatic cancer in which anorexia is a predominant symptom, not necessarily associated with cachexia, and are not attributed to anemia, concomitant illnesses, or obstruction or loss of organ function.
  • Karnofsky performance status of 40%
  • Palliative Prognostic Score (PaP) of less than 6
  • Patient is expected to be able to remain on a study protocol for two months.
  • Pretreatment laboratory data within 7 days of enrollment:
  • Hemoglobin >8.5 g/dL , or on stable doses (hematocrit stable within 1 gram and dose stable for one month) of erythropoietin or similar medication.
  • Absolute neutrophil count (ANC) 1,500/mm3.
  • Platelets 50,000/mm3.
  • Total bilirubin 2.0
  • ALT and AST 2.5 times the ULN, or, if the patient has liver metastases, 5 times the ULN.
  • Creatinine 1.5 mg/dL.
  • Normal TSH
  • Testosterone levels determined.
  • Voluntary written informed consent before performance of any study-related procedure that is not part of normal medical care.
  • Ability to self-administer subcutaneous medication if an assistant or nurse is not available, and to keep a compliance journal documenting injections at home.
  • If on an antidepressant, the dose must have been stabilized for at least 30 days.
  • Female patient is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of the study.
  • Male patient agrees to use an acceptable barrier method for contraception during the study

Exclusion Criteria:

  • Patient has uncontrolled brain metastases or central nervous system disease.
  • Patient has mechanical, non-reversible reason for not being able to eat, or have a potential for developing malignant bowel obstruction during the course of the induction phase of treatment, or patients requiring a PEG for obstruction.
  • Patient has had any major surgery within four weeks of enrollment.
  • Patient has an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • In the Investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  • Female patient is pregnant or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00765466

Layout table for location information
Canada, Quebec
McGill University Clinical Research Program
Montreal, Quebec, Canada, H2W 1S6
Sponsors and Collaborators
McGill University
Layout table for investigator information
Study Director: Maribel de Diego, Ph.D. Advances Viral Research Corporation
Layout table for additonal information
Responsible Party: Dr. Martin Chasen, McGill University Identifier: NCT00765466    
Other Study ID Numbers: McG 0710
First Posted: October 3, 2008    Key Record Dates
Last Update Posted: March 14, 2019
Last Verified: March 2007
Keywords provided by McGill University:
Explore the effect of AVR118 4.0 mL, given subcutaneously on appetite
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms